Allergan Posts Strong 4Q and Favorable Acute Migraine Results; Shares Undervalued
Between wide-moat Allergan’s strong fourth-quarter results, decent phase 3 trial results for ubrogepant in acute migraine, and announcement of a new CFO, we’re relatively encouraged by the company’s performance. While this quarter’s 12% top-line growth matched our forecast, $4.86 in adjusted earnings per share and $2 billion in operating cash flow slightly surpassed our expectations. More important, management’s 2018 outlook for $15 billion-$15.3 billion in revenue, adjusted EPS of $15.25-$16, a...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.